Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Gastrointestinal Neoplasms × ulixertinib × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 2 Neoplasms 1 Melanoma 1 Gastrointestinal Neoplasms 1 Colorectal Neoplasms 1

Interventions

Oxaliplatin 5 S 1 (combination) 4 Irinotecan 4 pembrolizumab 3 Fluorouracil 3 amminedichloro(2-methylpyridine)platinum(II) 2 N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 2 MLN 8237 2 Leucovorin 2 IFL protocol 2 Gemcitabine 2 Fecal Microbiota Transplantation 2 Drug Therapy 2 Doxorubicin 2 Cisplatin 2 Capecitabine 2 CGX1321 2 Bevacizumab 2 ulixertinib 1 tivozanib 1 titanium silicide 1 tislelizumab 1 sodium thiosulfate 1 sacituzumab govitecan 1 remune 1 phosphatidyltransferase, Clostridium butyricum 1 pazopanib 1 neratinib 1 motexafin gadolinium 1 montanide ISA 51 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04145297 2024-11-18

UTAH

University of Utah

Phase 1 Completed

Gastrointestinal

Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡